A laboratory-designed molecule inspired by nature offers a promising alternative for coeliac disease

From left to right, Francisco José López Cano, Arturo Rodríguez-Banqueri, F. Xavier Gomis-Rüth and Marina Girbal González.
Photo Credit: Courtesy of University of Barcelona

Scientific Frontline: Extended "At a Glance" Summary: Celiacase and Celiac Disease Therapeutics

The Core Concept: Celiacase is a molecularly engineered enzyme designed to break down toxic gluten immunogenic peptides (GIPs) in the stomach before they can reach the small intestine and trigger an autoimmune response.

Key Distinction/Mechanism: Unlike existing glutenases that require a neutral pH and high doses to function in the duodenum, celiacase operates highly effectively at very low concentrations in the acidic environment of the stomach (pH 2). It works synergistically with pepsin and completely deactivates upon reaching the intestine, preventing unintended interference with other proteins in the body.

Major Frameworks/Components:

• Pathophysiology of Celiac Disease: Prolamins (such as wheat gluten) break down during digestion into toxic peptides, most notably the highly immunogenic α-gliadin '33-mer' fragment.
• Autoimmune Trigger Mechanism: The binding of GIPs to the human leukocyte antigen (HLA) receptor in the small intestine, which initiates a damaging inflammatory response.
• Molecular Engineering: The derivation, structural design, and optimization of the celiacase molecule based on the naturally occurring nephrosin enzyme.
• In Vivo Validation: Efficacy demonstrated in a specialized mouse model, exhibiting reductions in intestinal atrophy, inflammation, antibody responses, and dysbiosis, alongside the restoration of normal immunoregulatory markers and microbial metabolic pathways.

ROCK2 Inhibitors for Schizophrenia Cognitive Deficits

Microscopy images showing dendrites, the rod-like branches of brain cells, with tiny protrusions called dendritic spines that are critical for memory and learning. Normal mice show similar spine density with (bottom left) and without KD025 treatment (top left). In mice carrying schizophrenia-associated gene variants, the tiny protrusions are visibly reduced without treatment (top right) but restored after KD025 treatment (bottom right). Scale bar: 5 μm.
Image Credit: Tanaka et al., 2026 

Scientific Frontline: Extended "At a Glance" Summary: Selective ROCK2 Inhibition in Schizophrenia

The Core Concept: Selective inhibition of Rho kinase 2 (ROCK2) via the drug KD025 is a novel therapeutic approach aimed at improving cognitive impairments and behavioral abnormalities in schizophrenia.

Key Distinction/Mechanism: Unlike current antipsychotic medications that primarily target positive symptoms but often cause severe metabolic and motor adverse effects, KD025 selectively inhibits ROCK2 to restore dendritic spine density in the prefrontal cortex without inducing hypotension or extrapyramidal symptoms.

Major Frameworks/Components:

• ARHGAP10 Gene Variant: A genetic mutation identified in patients that alters the activity of Rho-kinase (ROCK) signaling and neuronal stability.
• ROCK2 (Rho kinase 2): A specific kinase subtype heavily expressed in the brain that regulates brain cell function and neural connectivity.
• KD025: A ROCK2-selective inhibitor utilized to alleviate deficits in working memory, thinking, and visual discrimination.
• Dendritic Spine Density: The structural connectivity of neurons in the prefrontal cortex, which is often degraded in schizophrenia and shown to be restored via selective ROCK2 inhibition.

Testing cefiderocol and levofloxacin against hemorrhagic pneumonia

Hemorrhagic pneumonia in treatment groups
Compared to the control, LVFX and CFDC administered groups showed decreased lung damage.
  Image Credit: Osaka Metropolitan University

Scientific Frontline: Extended "At a Glance" Summary: Testing Antimicrobials Against Hemorrhagic Pneumonia

The Core Concept: A recent study evaluates the efficacy of two antimicrobial agents, cefiderocol (CFDC) and levofloxacin (LVFX), as treatments for severe hemorrhagic pneumonia caused by the multidrug-resistant bacterium Stenotrophomonas maltophilia.

Key Distinction/Mechanism: Both drugs improve survival rates and reduce bacterial burdens in the heart and lungs. LVFX provides more pronounced protection against lung hemorrhage because it more readily reaches pulmonary tissue; however, CFDC serves as a highly effective alternative when facing LVFX-resistant bacterial strains.

Major Frameworks/Components:

• Stenotrophomonas maltophilia: A multidrug-resistant pathogen that causes life-threatening infections in immunocompromised individuals.
• Levofloxacin (LVFX): A standard, highly effective antibiotic that is currently facing increasing rates of bacterial resistance.
• Cefiderocol (CFDC): A newer antimicrobial agent tested as a fallback therapeutic option.
• In vivo Murine Model: Utilized to measure overall survival rates, organ-specific bacterial burden, and microscopic hemorrhagic damage in lung tissue.

UChicago chemists invent new way to swap nitrogen into molecules

A new technique allows researchers to more quickly create new molecules by easily swapping nitrogen atoms in the place of carbonyl groups, which may help speed the process of drug discovery
Image Credit: Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: Carbonyl-to-Nitrogen Atom Swapping

The Core Concept: A novel chemical technique that enables researchers to customize molecules by directly swapping carbon-oxygen pairs (carbonyl groups) for nitrogen atoms.

Key Distinction/Mechanism: Unlike traditional structural modifications that require up to ten labor-intensive steps to construct a new molecular iteration, this method utilizes an ingredient called NAHA to cleave the carbonyl bond and directly insert a nitrogen atom into the empty space.

Major Frameworks/Components:

• Small-Molecule Scaffold Modification: Editing pre-existing molecular structures instead of building entirely from scratch.
• NAHA-Mediated Cleavage: Utilizing specific reagents to selectively break paired carbon-oxygen bonds.
• Functional Group Tolerance: Maintaining the stability and successful integration of other complex chemical attachments during the nitrogen substitution process.

Personalized Therapies for Rett Syndrome

Caption:Researchers grew advanced 3D cultures of human brain tissue from induced pluripotent stem cells to model specific Rett syndrome genetic mutations. Images from the research show organoids labeled to indicate cell types and electrical activity (via calcium imaging). Top: Purple staining highlights excitatory neurons, while white staining labels inhibitory neurons. Bottom left: Magenta shows jRGECO1a calcium imaging. Bottom right: Green highlights inhibitory neuron labeling with DLX-EGFP.
Image Credit: Tatsuya Osaki

Scientific Frontline: Extended "At a Glance" Summary: Personalized Treatments for Rett Syndrome

The Core Concept: A recent MIT study demonstrates that different mutations within the MECP2 gene, which causes Rett syndrome, result in distinct neurological abnormalities and require targeted, mutation-specific treatments rather than a universal therapeutic approach.

Key Distinction/Mechanism: Unlike previous research that simply knocked out the MECP2 gene entirely, this study utilized 3D human brain "organoids" (minibrains) derived from patient cells to model specific point mutations (R306C and V247X). This precise modeling revealed that each mutation causes unique structural, functional, and molecular deviations, such as differing neural network efficiencies and divergent gene expression profiles.

Major Frameworks/Components:

• 3D Brain Organoids: Advanced lab cultures grown from patient skin or blood cells, used to replicate a three-dimensional neural environment for accurately modeling genetic mutations.
• Three-Photon Microscopy: A high-resolution imaging technique used to visualize the structural layers of the 1-millimeter thick organoids and map the live calcium fluorescence activity of individual neurons.
• Single-Cell RNA Sequencing: An analytical method utilized to identify hundreds of variations in gene expression between the mutant organoids and control samples.
• Small-World Propensity (SWP): A measurable metric of neural network structure efficiency that decreased in R306C mutations but increased in V247X mutations.

Neuropharmacology: In-Depth Description

Neuropharmacology is the scientific study of how drugs affect cellular function in the nervous system and the neural mechanisms through which they influence human and animal behavior. The primary goals of this discipline are to map the complex interactions between chemical agents and neural networks, understand the fundamental molecular aspects of neurobiology, and translate these discoveries into targeted, efficacious therapeutic interventions for neurological and psychiatric disorders.

Using plants to fight Ebola and COVID-19

Michel Chrétien, professor emeritus at the Faculty of Medicine, Université de Montréal.
Photo Credit: Amélie Philibert, Université de Montréal.

Scientific Frontline: Extended "At a Glance" Summary: Dicitriosides as Novel Antivirals

The Core Concept: Dicitriosides are newly identified triterpenoid compounds discovered in a plant extract that demonstrate potent, broad-spectrum antiviral activity against the Ebola virus and SARS-CoV-2. These rare natural molecules offer significant therapeutic potential at pharmacologically achievable concentrations.

Key Distinction/Mechanism: Previously, the antiviral effects of this plant extract were mistakenly attributed to isoquercitrin, a common flavonoid. Using advanced analytical methods, researchers pinpointed that these two obscure dicitriosides—comprising only 0.4% of the extract—were actually responsible for the activity and proved up to 25 times more effective than the original extract.

Major Frameworks/Components:

• Bioassay-Guided Isolation: A rigorous analytical approach used to trace and identify the microscopic amounts of active dicitriosides within a complex botanical mixture.
• Multilevel Residual Complexity Analysis: The methodological framework employed to reveal the origin of the nanomolar antiviral bioactives previously masked by 'isoquercitrin'.
• Triterpenoid Compounds: The specific chemical classification of the two newly discovered dicitriosides.

Model study on the antiepileptic drug valproate: Influence on early brain development

Brain research in the Petri dish: Organoids can be used to understand disease processes.
Photo Credit: Amadeus Bramsiepe, KIT

Scientific Frontline: Extended "At a Glance" Summary: Valproate and Early Brain Development

The Core Concept: A recent study utilizes 3D human brain organoids to investigate how the widely used antiepileptic drug valproate disrupts early fetal brain development and contributes to neurodevelopmental disorders.

Key Distinction/Mechanism: Researchers discovered that valproate alters the extracellular microenvironment, making it stiffer. This physical and structural change inhibits cell proliferation, disrupts key developmental zones, and impairs the crucial signaling required for progenitor cells to properly mature into functional nerve cells.

Major Frameworks/Components: 

• Human Brain Organoids: 3D tissue structures grown in the laboratory from stem cells, used to simulate and observe human prenatal brain development over a 30-day drug exposure period.
• Extracellular Environment Analysis: Investigating how the structural and mechanical stiffening of the space surrounding cells impairs central neural communication.
• Multiomics Profiling: Evaluating the valproate-induced alterations simultaneously across tissue, cellular, and molecular levels.

Mini-Antibodies Reactivate the Guardian of the Genome

Structure of the DNA-binding domain of a reactivated p53 cancer mutant in complex with a stabilizing DARPin.
Image Credit: Andreas Joerger, Goethe University Frankfurt

Scientific Frontline: Extended "At a Glance" Summary: Mini-Antibodies Reactivating p53

The Core Concept: The p53 protein, widely known as the "guardian of the genome," is a crucial tumor suppressor that is mutated in approximately half of all cancer cases; researchers have engineered miniature antibodies called DARPins to stabilize these mutated proteins and restore their protective function.

Key Distinction/Mechanism: Unlike traditional small-molecule therapies that are constrained to targeting single, specific mutations, DARPins can selectively bind to and stabilize a vast array of different p53 mutants simultaneously. Furthermore, while conventional antibodies strictly target extracellular proteins, this new approach uniquely targets and operates on proteins inside the cell.

Origin/History: Developed by a scientific consortium comprising research groups from Goethe University Frankfurt, Philipps University Marburg, the University of Cologne, and the University of Zurich.

Targeted therapy drug shows early promise against KRAS-driven lung and pancreatic cancers

Image Credit: Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: Setidegrasib and KRAS G12D Targeted Therapy

The Core Concept: Setidegrasib is an investigational targeted therapy drug designed to attack and eliminate KRAS G12D, a critical cancer-driving protein responsible for advanced lung and pancreatic cancers.

Key Distinction/Mechanism: Unlike most conventional targeted therapies that function by merely blocking or inhibiting cancer-driving proteins, setidegrasib actively degrades and removes the abnormal KRAS protein from within the cancer cells.

Major Frameworks/Components:

• KRAS G12D Mutation: A prominent genetic driver occurring in approximately 40% of pancreatic ductal adenocarcinomas and 5% of non-small-cell lung cancers.
• Protein Degradation Pathway: A therapeutic mechanism that successfully reduces levels of the targeted KRAS G12D protein in tumors and lowers the amount of circulating tumor DNA in the bloodstream.
• Clinical Efficacy Profile: Early trial results demonstrated tumor shrinkage in 36% of participating non-small-cell lung cancer patients and 24% of pancreatic cancer patients at the recommended 600-mg weekly intravenous dose.

What Is: Biologic Medication

Visualization depicts a bio-engineered nanoparticle precisely delivering its therapeutic payload of complex protein molecules directly to a specific cellular receptor. This targeted interaction, derived from living sources, illustrates the sophisticated mechanism of a biologic medication within the body's vast biological landscape.
Image Credit: Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: Biologic Medication"

The Core Concept: Biologic medications are immense, highly complex therapeutic mixtures derived directly from living natural sources—such as human, animal, or microorganism cells—rather than being chemically synthesized. They represent a transformative paradigm shift in medicine, moving from the discovery of simple chemical compounds to the precise engineering of biological machinery to treat complex diseases.

Key Distinction/Mechanism: Unlike traditional "small-molecule" drugs (e.g., ibuprofen), which have low molecular weights, simple structures, and target deep intracellular pockets, biologics are massive proteins that engage the broad, flat surfaces of challenging protein-protein interactions. While small molecules can be synthesized identically and taken orally, biologics require complex cellular manufacturing—where "the process is the product"—and must be administered via injection or infusion to avoid gastrointestinal degradation.

Origin/History: The rudimentary use of biological agents spans centuries, notably beginning with 10th-century smallpox inoculations and Edward Jenner's 1796 vaccine. The modern scientific frontline of biologics was established in 1949 via in vitro cellular factories, culminating in the genetic revolution that yielded human recombinant insulin in 1982 (the first bioengineered drug) and the introduction of monoclonal antibodies in 1986.

Skin-deep microneedle sensor tracks drug clearance and reveals early kidney and liver dysfunction

The new microneedle sensor provides continuous, minimally invasive monitoring in skin. “We show that measurements taken just a millimeter beneath the skin can reveal clinically actionable information about organs deep inside the body,” said UCLA professor Sam Emaminejad.
Photo Credit: Emaminejad Lab/UCLA

Scientific Frontline: Extended "At a Glance" Summary: Microneedle Sensor for Drug Clearance and Organ Dysfunction

The Core Concept: A wearable, minimally invasive microneedle platform designed to continuously monitor the concentration of medically important molecules, such as pharmaceutical drugs, just beneath the surface of the skin.

Key Distinction/Mechanism: Unlike traditional blood tests that provide isolated snapshots of a patient's drug levels, this sensor allows for real-time, continuous tracking for up to six days. It achieves enhanced durability and sensitivity through a strongly adhered gold coating featuring nanoscale cavities; this architecture increases the sensing surface area nearly a hundredfold while protecting the delicate sensing molecules from tissue abrasion and biological buildup.

Major Frameworks/Components:

• Nanoscale Cavity Architecture: Microscopic surface depressions on the gold-coated needles that shield sensing molecules from friction and protein buildup, while exponentially expanding the active detection area.
• Continuous Pharmacokinetic Tracking: The physiological measurement framework that maps the rise and fall of drug concentrations in the body over extended periods to precisely infer the metabolic processing rates of internal organs.
• Multi-Target Compatibility: A highly sensitive and versatile design capable of supporting diverse sensing chemistries—including DNA-based mechanisms and engineered antibodies—allowing future iterations to track multiple distinct molecules simultaneously from a single patch.

Neurobiologists Hack Brain Circuits Tied to Placebo Pain Relief

Fluorescent images of a key brain circuit involved in placebo pain relief in mice. Pain-regulating neurons located in the ventrolateral periaqueductal gray (vlPAG) are labeled in green, with their cell bodies visible as green spots and their wire-like axons extending to the brainstem to suppress pain.
 Image Credit: Janie Chang-Weinberg

Scientific Frontline: Extended "At a Glance" Summary: The Neurobiology of Placebo Pain Relief

The Core Concept: Placebo pain relief is a phenomenon where the brain generates its own painkilling response—specifically through the release of endogenous opioid neuropeptides—without the administration of active pharmaceutical treatments. It is an expectancy-driven process that empowers the brain to produce broad-spectrum pain reduction on demand.

Key Distinction/Mechanism: Unlike traditional opioid painkillers (like morphine) that flood the system and carry a high risk of addiction and off-target side effects, placebo pain relief relies on precise, native neural circuits linking the cortex to the brainstem and spinal cord. The mechanism centers on the activation of endogenous opioid signaling within a specific brain region known as the ventrolateral periaqueductal gray (vlPAG).

Major Frameworks/Components: 

• Reverse Translation Method: An experimental framework where human placebo conditioning protocols are adapted for murine models, bridging the gap between human clinical data and foundational neurobiology.
• Ventrolateral Periaqueductal Gray (vlPAG): The anatomical hub in the brain identified as the critical site for pain signaling and the release of native opioids during placebo trials.
• Endogenous Opioid Neuropeptides: Naturally occurring endorphins that act as the brain's internal painkillers.
• Photoactivatable Naloxone (PhNX): An innovative light-activated drug technology used to precisely control and block opioid receptors in real-time, verifying that internal opioid signaling is the primary driver of placebo relief.

What Is: Quorum Sensing

Scientific Frontline: Extended "At a Glance" Summary: Quorum Sensing

The Core Concept: Quorum sensing is a sophisticated, population-density-dependent communication mechanism that enables bacteria and other microorganisms to coordinate collective behaviors through the secretion and detection of specialized chemical signaling molecules.

Key Distinction/Mechanism: Unlike isolated cellular functions, quorum sensing operates as a biochemical network where chemical signals called autoinducers accumulate as the microbial population multiplies. Once the extracellular concentration reaches a critical threshold, they bind to specialized receptors, triggering synchronized, community-wide gene expression alterations that control behaviors such as bioluminescence, virulence, and biofilm formation.

Origin/History: While the evolutionary roots of these systems trace back approximately 2.5 billion years—when mechanisms like bioluminescence likely evolved to protect early bacteria from severe oxidative damage—modern foundational phenomena were first observed in 1968 in the marine bacterium Vibrio fischeri. Researchers Woody Hastings and Kenneth Nealson later determined these bacteria communicated via secreted molecules, a process initially termed "autoinduction" before "quorum sensing" was widely adopted in 1994.

New drug doubles one-year survival in pancreatic cancer trial

Clinical trial participant Matthew Husar lived for roughly two years after starting the trial. He is seen here with his wife Dona Husar.
Photo Credit: Madeline Husar.

Scientific Frontline: Extended "At a Glance" Summary: Elraglusib

The Core Concept: Elraglusib is an experimental drug that, when combined with standard chemotherapy, successfully doubled the one-year survival rate and reduced the overall risk of death by 38% in patients with metastatic pancreatic cancer during a randomized phase 2 clinical trial.

Key Distinction/Mechanism: Unlike traditional chemotherapy, which primarily aims to directly destroy cancer cells, elraglusib functions by targeting the protein GSK-3 beta to alter the tumor microenvironment. By inhibiting this protein, the drug mitigates tumor-driven immune suppression and increases the presence of cancer-fighting cells within the tumor, effectively re-engaging the body's natural immune response.

Major Frameworks/Components:

• GSK-3 Beta Inhibition: Targeting a specific protein known to drive tumor growth and actively suppress immunological responses.
• Microenvironment Modulation: Altering the biological ecosystem of cancer cells, immune cells, and surrounding tissue to counter aggressive immune evasion characteristic of pancreatic tumors.
• Combination Therapy: Synergizing the experimental microenvironment-altering drug with established cytotoxic chemotherapy protocols to improve overall survival metrics.
• Biomarker-Driven Efficacy: Utilizing baseline immune-related blood markers to identify patient populations whose immune systems are primed to exhibit prolonged survival.

Unlocking how dogs’ fungal ear infections evade treatment points vets to drug stewardship

Scientific Frontline: Extended "At a Glance" Summary: Antifungal Resistance in Canine Otitis Externa

The Core Concept: Recent veterinary research has identified that genetic mutations in specific yeast strains are responsible for the increasing resistance of canine fungal ear infections (otitis externa) to common topical antifungal treatments.

Key Distinction/Mechanism: Resistance is driven by mutations in the yeast's ERG11 gene, which alters the structure of the Erg11 protein—a critical component of the yeast cell membrane. This structural change prevents short-tailed azole antifungals, such as miconazole, from effectively binding to and neutralizing the yeast, whereas longer-tailed azoles like posaconazole possess more contact points and maintain clinical efficacy.

Origin/History: Published in April 2026 by researchers at the University of Illinois Urbana-Champaign, including pathobiologist Lois Hoyer and veterinary dermatologist Dr. Clarissa Pimentel de Souza. The study was initiated in response to the rising clinical prevalence of persistent, recurrent fungal ear infections in dogs that failed to respond to standard topical treatments.

Largest-ever study of psychedelics could help advance their use in treating mental health disorders

Image Credit: Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: Common Neural Mechanisms of Psychedelics

The Core Concept: Despite their distinct chemical compositions, various psychedelic compounds—including psilocybin, LSD, mescaline, DMT, and ayahuasca—produce a unified, common pattern of brain activity.

Key Distinction/Mechanism: The shared neurological effect manifests through two distinct, measurable changes: the weakening of normally tight, highly organized neural networks (reduced intra-network connectivity) and a concurrent increase in communication between brain networks that are usually segregated (increased inter-network cross-talk). This boundary-crossing communication is theorized to drive the atypical perceptions, thoughts, and hallucinations associated with the psychedelic experience.

Origin/History: Following the "psychedelic research winter" of the 1970s characterized by criminalization and stigma, modern advances in brain imaging have fueled a scientific revival. In April 2026, an international consortium led by a McGill University researcher published the largest-ever meta-analysis on the subject in Nature Medicine, pooling 11 global datasets comprising over 500 brain imaging sessions from 267 participants.

Treating Tumors Independently of Oxygen

Johannes Karges and his team have developed a new mechanism of activity against cancer cells.
Photo Credit: © RUB, Marquard

Scientific Frontline: Extended "At a Glance" Summary: Hypoxic Photodynamic Therapy

The Core Concept: A novel photodynamic therapy (PDT) approach utilizing a ruthenium-based active agent to effectively destroy cancer cells even within severe, oxygen-depleted (hypoxic) tumor environments.

Key Distinction/Mechanism: Traditional photodynamic cancer treatments rely on the presence of ambient oxygen to create cell-killing reactive oxygen species, making them largely ineffective in the oxygen-starved centers of fast-growing tumors. This newly developed therapy circumvents the need for molecular oxygen entirely. When oxygen is absent, intracellular iron coordinates with the active agent, triggering an ultra-fast metal-to-metal electron transfer from the excited ruthenium center to the iron center. This process converts naturally occurring hydrogen peroxide within the cell into highly lethal hydroxyl radicals, which cause fatal oxidative damage to the cancer cells.

Major Frameworks/Components:

• Photodynamic Therapy (PDT): An established cancer treatment method where an administered, inactive substance is activated via targeted light irradiation.
• Ruthenium-Based Active Agent (Ru(II) Polypyridine–Deferasirox Conjugate): The light-activated compound capable of entering an excited electronic state to drive the reaction.
• Metal-to-Metal Electron Transfer: The alternate, oxygen-independent chemical pathway where electrons transfer from the ruthenium center to an iron center.
• Hydroxyl Radicals: Highly reactive, cell-destroying molecules generated by the conversion of cellular hydrogen peroxide during the electron transfer process.

Researchers find way to treat lung cancer and associated muscle wasting at the same time

Illustration shows depicts treating lung tumors with lipid nanoparticles loaded with follistatin.
Image Credit: Parinaz Ghanbari

Scientific Frontline: Extended "At a Glance" Summary: Dual-Targeted mRNA Therapy for Lung Cancer and Cachexia

The Core Concept: This novel therapeutic approach utilizes specialized lipid nanoparticles (LNPs) to deliver follistatin messenger RNA (mRNA) directly to lung tumors, simultaneously inhibiting cancer growth and reversing cachexia, a severe muscle-wasting syndrome.

Key Distinction/Mechanism: Unlike conventional LNPs, which typically accumulate in the liver following systemic administration, these modified LNPs bind to the blood serum protein vitronectin. The vitronectin directs the LNPs specifically to lung cancer tumors by interacting with integrin receptors that are overexpressed on the tumor surface. Once absorbed, the mRNA instructs the cells to produce follistatin, a protein known to suppress tumor progression and stimulate muscle tissue growth.

Major Frameworks/Components: 

• Lipid Nanoparticles (LNPs): Nanoscale delivery vehicles composed of fatty acids designed to carry genetic material intravenously without degrading.
• Follistatin mRNA: The therapeutic genetic payload that triggers the endogenous production of the dual-action follistatin protein.
• Vitronectin: A naturally occurring blood serum protein that binds to the LNPs and acts as a homing beacon.
• Integrin Receptors: Surface receptors overexpressed on lung cancer cells that interact with vitronectin to facilitate the precise cellular uptake of the LNPs.

Electroacupuncture shows promise in breast cancer survivors

“Patients often report feeling unprepared for the cognitive and emotional challenges that persist after treatment,” says the study’s corresponding author, Alexandre Chan, UC Irvine professor and founding chair of the Department of Clinical Pharmacy Practice. “We need robust scientific evidence to show how effective interventions can be integrated into their treatment in order to reduce survivors’ symptoms and improve their healing journeys.”
Photo Credit: Steve Zylius / UC Irvine

Scientific Frontline: Extended "At a Glance" Summary: Electroacupuncture in Post-Cancer Care

The Core Concept: Electroacupuncture is an integrative, non-pharmacological therapy that applies a mild electrical current to traditional acupuncture needles. It is utilized to improve persistent cognitive dysfunction and reduce psychological distress in breast cancer survivors.

Key Distinction/Mechanism: Unlike traditional acupuncture, electroacupuncture introduces mild electrical stimulation to targeted neuropsychiatric-specific acupoints. This localized approach has been shown to increase gray matter volume, improve brain network connectivity, and reduce blood-based biomarkers associated with neuroinflammation, offering a distinct alternative to symptom-management medications that carry dependency and interaction risks.

Major Frameworks/Components:

• Targeted Acupoint Stimulation: Focusing electrical stimulation on specific neuro-psychological functional points rather than non-specific control points.
• Neuroimaging Assessments: Utilizing brain imaging to track physical changes in gray matter volume and functional neural connectivity.
• Biomarker Analysis: Measuring blood-based markers to directly quantify reductions in systemic neuroinflammation.
• Cognitive and Psychological Testing: Quantifying measurable enhancements in attention and reductions in clinical distress.